Thought Leadership - 11.20.2020
Considerations for Internal Versus External Manufacturing for Developing Cell and Gene Therapies
Manufacturing has been widely recognized as a bottleneck to bring advanced therapies to the patients and families in need. Cell and gene therapy organizations are faced with a difficult decision on whether to build internal capabilities to resolve this bottleneck or look externally for their manufacturing needs.
Hosted by Precision Medicine Group and Informa Pharma Intelligence, this panel discussion will provide key inputs to consider when choosing between a make vs. buy, to scale-up manufacturing internally or look to an external supplier like a CDMO. You will hear from industry experts, including Project Farma EVP Tony Khoury, on the state of the advanced therapy industry, the investment that is pouring into advanced therapies, why manufacturing is such a critical component, various approaches to the build or buy decision and advantages and challenges of the decision.
The panel discussion will be followed by an interactive Q&A session.
After participation, you will:
- Understand the key factors that a cell and gene therapy should consider when deciding between scaling up manufacturing internally or using an external supplier
- Appreciate the state of the advanced therapy industry and why we need to resolve the manufacturing bottleneck to bring advanced medicines to the patients and families who need them
- Recognize that both solutions, build or buy, have their advantages and challenges and perhaps a hybrid solution may be the best approach.